{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022580","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.788146+00:00","generated_at":"2026-05-16T19:55:33.291721+00:00","sec_items":["1.01","1.02","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC","bullets":["Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.","Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.","Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).","Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.","ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022580","json":"https://secwatch.observer/filing/0001493152-25-022580.json","markdown":"https://secwatch.observer/filing/0001493152-25-022580.md","text":"https://secwatch.observer/filing/0001493152-25-022580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/0001493152-25-022580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:55:33.291721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}